Search Results - "Kitabatake, Shotaro"

A novel derivative (GTN024) from a natural product, komaroviquinone, induced the apoptosis of high-risk myeloma cells via reactive oxygen production and ER stress by Okayama, Mikio, Kitabatake, Shotaro, Sato, Mariko, Fujimori, Kota, Ichikawa, Daiju, Matsushita, Maiko, Suto, Yutaka, Iwasaki, Genji, Yamada, Taketo, Kiuchi, Fumiyuki, Hirao, Maki, Kunieda, Hisako, Osada, Makoto, Okamoto, Shinichiro, Hattori, Yutaka

“…New drugs have significantly improved the survival of patients with multiple myeloma (MM), but the prognosis of MM patients with high-risk cytogenetic changes…”
Get full text

Synthesis and biological evaluation of the natural product komaroviquinone and related compounds aiming at a potential therapeutic lead compound for high-risk multiple myeloma by Suto, Yutaka, Sato, Mariko, Fujimori, Kota, Kitabatake, Shotaro, Okayama, Mikio, Ichikawa, Daiju, Matsushita, Maiko, Yamagiwa, Noriyuki, Iwasaki, Genji, Kiuchi, Fumiyuki, Hattori, Yutaka

“…[Display omitted] Alternatives of treatments for multiple myeloma (MM) have become increasingly available with the advent of new drugs such as proteasome…”
Get full text

Komaroviquinone-Derivatives, Revealed Anti-Tumor Effect on High-Risk Multiple Myeloma Cells In Vitro as Well as In Vivo by Sato, Mariko, Fujimori, Kota, Kitabatake, Shotaro, Okayama, Mikio, Ichikawa, Daiju, Suto, Yutaka, Iwasaki, Genji, Kiuchi, Fumiyuki, Yamaguchi, Takashi, Ueda, Arimi, Aida, Shuji, Nakayama, Hitomi, Matsushita, Maiko, Hattori, Yutaka

“…Background: Recent progress in the treatment of multiple myeloma (MM) has improved its prognosis. However, the MM patients with high-risk cytogenetic…”
Get full text

Development of a Novel Phthalimide Derivative, Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts by Hattori, Yutaka, Matsushita, Maiko, Tabata, Noriko, Shiheido, Hirokazu, Yanagawa, Hiroshi, Ueda, Arimi, Hozumi, Masashi, Kitabatake, Shotaro, Ichikawa, Daiju

“…BACKGROUND: Despite recent advances in the use of newly developed drugs including immune-modulatory drugs (IMiDs) such as thalidomide, lenalidomide, and…”
Get full text

Drug Design for Overcoming High-Risk Myeloma and Identification of Novel Binding Proteins to Immune-Modulatory Drugs by Hozumi, Masashi, Ichikawa, Daiju, Matsushita, Maiko, Kamiyama, Eriko, Yanagawa, Hiroshi, Tabata, Noriko, Kitabatake, Shotaro, Ueda, Arimi, Yamaguchi, Takashi, Sato, Mariko, Hattori, Yutaka

“…PURPOSE: Recent progress of the treatment of multiple myeloma (MM) has significantly improved prognosis. However, the MM patients with high-risk cytogenetic…”
Get full text